COTA, MedStar Health partnership to use RWD in cancer research

By Jenni Spinner contact

- Last updated on GMT

(FatCamera/iStock via Getty Images Plus)
(FatCamera/iStock via Getty Images Plus)

Related tags: Cancer, Oncology, RWD, RWE, Clinical trials, Research

The oncology-centered analytics firm will work with the DC-area healthcare provider to delve into discovery and development of novel cancer treatments.

COTA, a real-world data (RWD) and analytics company focused on cancer treatments, has announced it is entering a new research partnership with MedStar Health, currently the largest healthcare provider in the Maryland/Washington, DC region. COTA reportedly will support MedStar Health in its use of RWD to accelerate scientific discoveries, and to improve the care of oncology patients.

The MedStar cancer treatment team (which includes the MedStar Health Cancer Network and the MedStar Georgetown Cancer Institute) delivers oncology care to patients across a total of 10 sites. The Institute’s academic cancer partner, Georgetown Lombardi Comprehensive Cancer Center, — is one of 51 comprehensive cancer centers in the nation to receive this designation by the National Cancer Institute.

Neil Weissman, president of MedStar Health Research Institute and chief scientific officer for MedStar Health, said the collaboration stands to benefit people living with cancer, and those who have not yet received a diagnosis.

Our partnership with COTA will support our ongoing efforts to leverage deep clinical data to power research that will improve outcomes for cancer patients​,” Weissman said. “As a leader in oncology real-world data, we are excited to work with COTA to drive innovative research that will change how cancer is studied and treated​.”

Louis Weiner, director of the Georgetown Lombardi Comprehensive Cancer Center and the MedStar Georgetown Cancer Institute, said effective collection and analysis of data can be hugely beneficial in discovering new oncological therapies.

Collecting and understanding data is becoming increasingly important to how we select cancer treatments for individuals​,” Weiner said. “The Institute’s research collaboration with COTA will help accelerate advances and enhance our goal of providing our patients with tomorrow’s cancer treatments, today​.”

COTA provides oncology real-world data abstraction, curation, and analytics capabilities to healthcare provider organizations and life sciences companies that are caring for and developing treatments for patients living with a wide range of cancers. The company combines oncology expertise with technology-enabled data abstraction techniques to curate meaningful, longitudinal, and de-identified datasets.

Mike Doyle, COTA’s CEO, said, “At COTA we serve as a critical bridge between healthcare providers and the researchers who can accelerate clinical development to make life-saving treatments available to patients faster. We are proud to collaborate with MedStar Health, a well-respected leader in oncology, to advance scientific discovery with representative and diverse real-world data​.”

Earlier this year, COTA announced a collaboration with researchers at the University of Chicago Medicine​. That partnership is geared toward studying disparities in care for people with multiple myeloma, a cancer that disproportionately impacts Black patients.

Related news

Show more

Related products

show more

GLP Tissue Cross Reactivity Testing

GLP Tissue Cross Reactivity Testing

Precision for Medicine | 11-Oct-2021 | Product Brochure

Precision for Medicine's unique combination of research services and tissue procurement capabilities form the pillars of our GLP Tissue Cross Reactivity...

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

Related suppliers

Follow us

Products

View more

Webinars